22 / 27
Page 67
conferenceseries
.com
Volume 7, Issue 7 (Suppl)
J Gastrointest Dig Syst
ISSN: 2161-069X JGDS, an open access journal
Gastroenterologists 2017
December 14-15, 2017
December 14-15, 2017 Dubai, UAE
11
th
World
Gastroenterologists Summit
Advances in inflammatory bowel disease
Subramanian Sreedhar
University of Liverpool, UK
T
he genetics of isolated colonic Crohn's disease place it approximately midway between Crohn's disease with small intestinal
involvement and UC, making a case for considering it as a separate condition. We have therefore systematically reviewed
its epidemiology, pathophysiology and treatment. Key findings include a higher incidence in females (65%) and older average
age at presentation than Crohn's disease at other sites, a mucosa-associated microbiota between that found in ileal Crohn's
disease and UC, no response to mesalazine, but possibly better response to anti-tumor necrosis factor than Crohn's disease
at other sites. Diagnostic distinction from UC is often difficult and also needs to exclude other conditions including ischemic
colitis, segmental colitis associated with diverticular disease and tuberculosis. Future studies, particularly clinical trials, but
also historical cohorts, should assess isolated colonic Crohn's disease separately. The therapeutic armamentarium in IBD is
expanding rapidly with the recent approval of new biological agents such as ustekinumab in Crohn’s disease and the imminent
approval of the JAK inhibitor tofacitinib. In addition, several new therapeutic approaches such as intensive fecal microbiota
transplantation in UC and new pipeline molecular therapeutics are on the horizon. This talk will provide a comprehensive
overview of new developments in the field of IBD.
Sreedhar.Subramanian@rlbuht.nhs.ukJ Gastrointest Dig Syst 2017, 7:7 (Suppl)
DOI: 10.4172/2161-069X-C1-062